Stem Cell Transplantation clinical trials at University of California Health
1 in progress, 0 open to eligible people
Sorry, not currently recruiting here
This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. The dose administered is 50 x 106 cells (flat dosing).